8-K Announcements
6Material company update
Jun 4, 2026·SEC
Material company update
May 22, 2026·SEC
Material company update
May 21, 2026·SEC
Coeptis Therapeutics Holdings, Inc.(COEPW)Earnings, Financials & Key Ratios
COEPW•NASDAQ
$0.01
Price updated Jun 20, 2026
AboutCoeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.Show more
- Revenue$1M
- EBITDA-$12M-31.1%
- Net Income-$12M-11.6%
- EPS (Diluted)-2.81+50.3%
- Gross Margin86.75%
- EBITDA Margin-867.24%
- Operating Margin-956.94%
- Net Margin-874.29%
- ROE-110.23%+57.8%
COEPW Price & Volume
Coeptis Therapeutics Holdings, Inc. (COEPW) stock price & volume — 10-year historical chart
Loading chart...
Persistent Cash Burn Challenges Clinical Development Viability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Insufficient cash runway
"Coeptis Therapeutics faces a precarious financial outlook characterized by sporadic, non-recurring revenue streams that fail to offset significant quarterly operating losses. The company's reliance on external capital to fund its clinical pipeline is evidenced by a massive accumulated deficit of $113.9M, which continues to erode shareholder equity. Investors should remain cautious as the firm's $5.2M cash position appears insufficient to sustain long-term research activities without further dilutive financing."
Verdict Logic
the company's reliance on external funding is underscored by a $113.9M accumulated deficit and a limited $5.2M cash balance that threatens future operational continuity.
COEPW Growth Metrics
Coeptis Therapeutics Holdings, Inc. (COEPW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years113.45%
3 Years-
TTM2148.85%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-21.48%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-183.07%
Return on Capital
10 Years-355.67%
5 Years-355.67%
3 Years-241.78%
Last Year-116.11%
COEPW Recent Earnings
Coeptis Therapeutics Holdings, Inc. (COEPW) EPS & revenue vs analyst estimates — last 4 quarters
Q3 2026Latest
Jun 3, 2026Metric
Actual
Est
EPS
$0.65
—
Rev
$113,771
—
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$0.28
—
Rev
$862,049
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.03
—
Rev
$237,441
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.95
—
Rev
$200,681
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 3, 2026 | $0.65 | $113,771 |
| Q2 2026 | Mar 19, 2026 | $0.28 | $862,049 |
| Q4 2025 | Nov 14, 2025 | $0.03 | $237,441 |
| Q3 2025 | Aug 14, 2025 | $0.95 | $200,681 |
Based on last 7 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Coeptis Therapeutics Holdings, Inc. (COEPW)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.01 | $22.01K | -0.00 | — | -874.29% | -110.23% | — | |
| $42.07 | $1.57B | -300.50 | 36.41% | -5.57% | -33.92% | — | |
| $5.65 | $1.96B | -9.42 | 698.96% | -102.06% | -44.1% | — | |
| $5.41 | $2.8B | -31.82 | 40.34% | -2.58% | -17.08% | — | |
| $4.39 | $435.96M | -5.78 | -22.61% | -137.08% | — | — | |
| $327.79 | $9.47B | -24.32 | -100% | — | -43.02% | — |
Compare COEPW vs Peers
Coeptis Therapeutics Holdings, Inc. (COEPW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
COEPW SEC Filings & Documents
Coeptis Therapeutics Holdings, Inc. (COEPW) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when COEPW posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
COEPW Frequently Asked Questions
Coeptis Therapeutics Holdings, Inc. (COEPW) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Coeptis Therapeutics Holdings, Inc.'s revenue?
Coeptis Therapeutics Holdings, Inc. (COEPW) reported $1.4M in revenue for fiscal year 2025.
Is COEPW profitable?
Coeptis Therapeutics Holdings, Inc. (COEPW) reported a net loss of $11.9M for fiscal year 2025.
Dividend & Returns
What is COEPW's return on equity?
Coeptis Therapeutics Holdings, Inc. (COEPW) has a return on equity (ROE) of -110.2%. Negative ROE indicates the company is unprofitable.
What is Coeptis Therapeutics Holdings, Inc.'s free cash flow?
Coeptis Therapeutics Holdings, Inc. (COEPW) had negative free cash flow of $8.0M in fiscal year 2025, likely due to heavy capital investments.